Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 May 26;16(5):e0251502. doi: 10.1371/journal.pone.0251502

“Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

Andrés Hernández 1,2,3, Minxuan Lan 2, Neil J MacKinnon 4,5, Adam J Branscum 6, Diego F Cuadros 1,2,5,*
Editor: Arsham Alamian7
PMCID: PMC8153501  PMID: 34038441

Abstract

The United States (U.S.) is currently experiencing a substance use disorders (SUD) crisis with an unprecedented magnitude. The objective of this study was to recognize and characterize the most vulnerable populations at high risk of SUD mortality in the U.S., and to identify the locations where these vulnerable population are located. We obtained the most recent available mortality data for the U.S. population aged 15–84 (2005–2017) from the Centers for Diseases and Prevention (CDC). Our analysis focused on the unintentional substance poisoning to estimate SUD mortality. We computed health-related comorbidities and socioeconomic association with the SUD distribution. We identified the most affected populations and conducted a geographical clustering analysis to identify places with increased concentration of SUD related deaths. From 2005–2017, 463,717 SUD-related deaths occurred in the United States. White population was identified with the highest SUD death proportions. However, there was a surge of the SUD epidemic in the Black male population, with a sharp increase in the SUD-related death rate since 2014. We also found that an additional average day of mental distress might increase the relative risk of SUD-related mortality by 39%. The geographical distribution of the epidemic showed clustering in the West and Mid-west regions of the U.S. In conclusion, we found that the SUD epidemic in the U.S. is characterized by the emergence of several micro-epidemics of different intensities across demographic groups and locations within the country. The comprehensive description of the epidemic presented in this study could assist in the design and implementation of targeted policy interventions for addiction mitigation campaigns.

Introduction

Substance use disorders (SUD) have been declared one of the top public health priorities in the United States (U.S.), with 185 SUD-related deaths, on average, each day in 2018 [1, 2]. SUD disorders are considered a subgroup of the addiction diseases that are deemed as mental health conditions in which a person repeatedly uses substances or engages in behaviours with the knowledge of their harmful consequences [3]. In the U.S., it is estimated that one in five people aged 12 years or older used an illicit drug, and 8.1 million had an illegal drug use disorder in 2018 [4], with 67,367 reported deaths by drug overdose in the same year [1, 2]. Overall, the U.S. mortality rate related to SUD reached 20.7 deaths per 100,000 inhabitants in 2018, with West Virginia (51.5), Delaware (43.8), Maryland (37.2), Pennsylvania (36.1), Ohio (35.9), and New Hampshire (35.8), having the highest mortality rates at the state level [2].

Several studies have examined multiple characteristics of the addiction epidemic in the U.S. These studies have reported a significant increase in mortality rates from 2010, with its highest peak in 2017, and a considerable demographic and spatial heterogeneity of the epidemic being attributed, in part, to the uneven distribution of several demographic and socioeconomic factors and health comorbidities across the country [57]. However, previous studies have not fully explained the reasons behind the unequal spread of the SUD epidemic and there remains a need to reduce the high level of SUD-related mortality rates in the country. As a result, several sociological studies have suggested the need for implementing a socio-ecological framework to conceptualize the drivers of addictive behaviours according to their level of influence in order to design effective strategies [8, 9]. These studies highlight the importance of the interconnection between individual and broader social and environmental domains as essential to understanding the SUD epidemic. Within this framework, individual, family, neighborhood, and community-level attributes have been identified as potential drivers of the current SUD epidemic [79]. Furthermore, our preliminary study conducted in Ohio identified different spatial and demographic distributions associated with the opioid overdose deaths in the state, such that the epidemic is concentrated in specific demographic groups and locations, with multiple spatial and temporal sub-epidemics emerging at distinct time periods [10].

Successful approaches like the “Know your epidemic, know your response” framework implemented for counteracting the malaria and HIV epidemics worldwide have resulted in mitigation policies that shifted from intervention strategies (i.e. vaccines, medical treatment) to targeted prevention plans (i.e. modifying behavioral response of individuals) [11]. The core of the “Know your epidemic, know your response” approach is the identification of the environmental, socioeconomic, and demographic drivers of an epidemic [6, 12, 13]. These drivers become the cornerstones of the design and implementation of prevention measures that target vulnerable populations under their unique social, environmental, and epidemiological circumstances [11]. Moreover, “Know your epidemics, know your response” approach highlights the role of the individual awareness of the risk in the ability to respond with appropriate mitigation strategies, allowing to focus on education efforts and mitigation of risk factors, more than in allocating resources for intervention policies [14]. Similar to malaria and HIV, addiction disorders are characterized by complex spatial hierarchical structures caused by multiple concurrent sub-epidemics of different intensities among different populations [11]. However, in the case of SUD-related mortality rates, the link between community-level factors and risk of death is not well understood. In addition, the vulnerable populations suffering the highest burden of the SUD epidemic driven by specific socioeconomic characteristics and comorbidities are still not well characterized. Epidemiologic research to resolve these complexities should address the spatial and hierarchical nature of the epidemic to estimate associations between individual- and community-level attributes and SUD-related mortality.

Against this background, we used data from the U.S. Centers for Disease Control and Prevention (CDC) on individual mortality from 2005–2017 to analyze the demographical, spatial, and temporal structure of the SUD epidemic and its associated risk factors in the U.S. In accordance with the “Know your epidemic, know your response” approach, the aim of this study is two-fold: (i) to identify and characterize the demographic groups at highest risk of death by SUD, and (ii) to describe the spatial and temporal dynamics of the SUD epidemic in the U.S. We aimed to identify the key demographic factors associated with the epidemic, and the vulnerable populations and places where the burden of the epidemic is concentrated. A nationwide description of the epidemic would assist in the design and implementation of targeted policy interventions for addiction mitigation campaigns through an understanding of the spatial variability and epidemiological profiles in the U.S.

Research methods

Data sources description, sampling, and demographic analysis

Data were provided by the CDC from restricted-use vital statistics micro-data files for the period of January 2005 to December 2017, which is the latest available mortality data at the time of the analysis [15]. Available data included the date and county of death, demographic characteristics of individuals (sex, race, age, marital status, and educational level) and the International Classification of Diseases, 10th Revision (ICD-10) code for the cause of death [16]. We extracted information about drug overdose deaths for individuals aged 5 to 84 years from ICD-10 codes for unintentional substance poisoning. Monthly death rates by county were computed as the ratio of the number of SUD deaths to the number of total deaths and were scaled by 1,000.

Community-level factors related to health behaviours and physical and mental health at the county level were retrieved from the County Health Rankings & Roadmaps program from 2010 to 2017 [17]. These covariates corresponded to social and health risk factors that have been associated with SUD in previous studies at the community level [9, 18, 19]. We included the self-reported number of days per month under physical and mental distress, excessive adult drinking, and tobacco consumption from the Behavioral Risk Factor Surveillance System (BRFSS) [20]. We also included the percent of children living in poverty and the population without health insurance in each county as potential socioeconomic factors associated with the SUD epidemic.

In addition, from the complete data set provided by the CDC, we performed stratified random sampling with strata given by year and state of death occurrence to avoid requiring excessive computational resources for regression analysis [21, 22]. Finally, SUD death rates by demographic groups were visualized using time series graphs and heat maps to describe the temporal dynamics of the SUD epidemic from 2005 to 2017. We computed death rates by race, gender, and age group to determine the groups most affected by the epidemic. Demographic analysis was conducted using the complete data and also data from the stratified random sampling. Institutional Review Board Approval was not necessary for this study because all data were deidentified and publicly available.

Risk factors associated with mortality caused by substance use disorders

We conducted logistic regression analyses of data collected from stratified random sampling to identify individual- and community-level factors associated with the odds of SUD-related mortality. The binary outcome variable for each study subject was death by SUD (y = 1) or death by other causes (y = 0). Individual-level covariates were age group (by quinquennial), race (White, Black, other), sex (female, male), educational level (primary, secondary, college or higher), and marital status (never married, currently married, and previously married). The logistic regression model was implemented using a mixed effects generalized additive model [23] (GAM) that allowed for nonlinear trends for all of the community-level covariates (individual-level covariates are all categorical) [24]. Our primary analysis used a logistic regression GAM mixed model for evaluating associations between individual- and community-level covariates and SUD-related mortality without including interaction terms. A supplementary analysis added interaction terms between individual- and community-level covariates (mental and physical health) to the model. All logistic regression models included a random effect for county. All sampling operations were conducted using Python 3.8 [25], and Spark 4.1 [26] with the pyspark package, and statistical analyses were conducted using R version 3.5.2 (R Project for Statistical Computing) [27] with the mgcv 1.8–31 package [28].

Cluster analysis and spatiotemporal risk estimation

Spatial clusters of SUD-related deaths were identified using scan statistics implemented in the SaTScan software [29]. Locations in the U.S. where the number of deaths due to SUD was higher than expected under the null hypothesis of a homogeneous distribution of SUD related deaths were classified as hotspots. The number of SUD-related deaths from the complete dataset at the county level from 2005 to 2017 were analyzed using a Poisson model with the total number of deaths from any cause by county included as an offset. Resulting hotspots were selected based on having p-values less than 0.05 and filtered to contain at least three counties and non-overlapping clusters. Community-level covariates were computed for each hotspot, all hotspots combined, and non-hotspot areas.

In addition, we assessed the spatial and spatiotemporal dynamics of the relative risk (RR) of SUD-related mortality using a Bayesian zero-inflated Poisson regression model to accommodate excess zero counts in sparse area data in the context of a Besag-York-Mollie (BYM) model [30]. The spatial analysis was computed by counties within the contiguous U.S. with available community-level information and was applied to the total number of deaths from 2005 to 2017, while the spatiotemporal study used the deaths by county, aggregated by semester from 2005 to 2017. The model was fitted using an integrated nested Laplace approximation implemented in the R-INLA software package [31]. Results of these analyses were mapped using the R statistical software along with the ggplot2 [32] library for spatial visualization. Extended details of the methods can be found in the S1 Text.

Results

General demographic profile of the SUD epidemic in the U.S.

Table 1 presents the distribution of deaths caused by SUD in the selected demographic groups, with 463,717 SUD-related deaths (2.04%) among the total number of deaths (22,705,614) registered in the U.S. from 2005 to 2017. Males had a higher proportion of SUD-related deaths (2.38%) compared to females (1.61%) in all racial groups. Additionally, the proportion (2.14%) of SUD-related deaths for the White population was higher than that for the Black population (1.60%), and other races (1.37%). Fig 1 illustrates the temporal trajectories of SUD-related death rates per 1,000 total deaths by race and sex, with the White male population consistently having the highest SUD-related mortality rates from 2005 to 2017. However, SUD-related death rates for Black males have increased sharply since 2014, going from 18.91 (2014–01) to 38.65 (2017–12) with a percentage change (PC) of 104,38%, compared to the White males increase from 26.46 (2014–01) to 39.77 (2017–12), PC: 50.30%. In addition, the heat maps in Fig 2A and 2B show the temporal patterns of SUD death rates by race, sex, and age groups, and indicate a concentration of SUD-related deaths among individuals aged 15 to 39 in both sexes and all race groups, with an additional clustering of deaths in Black males aged 40–49. Fig 2A illustrates the SUD-related mortality rates peaking for white population during the first semester of 2017 with the highest rates on White young males (350 SUD-deaths per 1,000 total deaths), in contrast to the Black young males (Fig 2B) with 140 SUD-related deaths per 1,000 total deaths. The substance discrimination analysis, which identified different substances leading the epidemic in different populations, is included in the S1 Fig.

Table 1. Number of deaths in the United States caused by Substance Use Disorders (SUD) and all other causes from 2005 to 2017.

Risk Factor Deaths by SUD Deaths by any other cause Proportion of SUD Deaths
Age Group
< 15 377 73,303 0.51%
15–19 8,347 139,728 5.64%
20–24 34,544 226,495 13.23%
25–29 50,657 237,945 17.55%
30–34 54,039 265,932 16.89%
35–39 53,456 345,450 13.40%
40–44 56,154 528,421 9.61%
45–49 64,612 870,268 6.91%
50–54 61,052 1,357,145 4.30%
55–59 43,568 1,854,540 2.30%
60–64 21,220 2,282,678 0.92%
> 64 15,570 14,046,878 0.11%
Not Available 121 13,114 0.91%
Sex
Females 159,520 9,754,240 1.61%
Males 304,197 12,487,657 2.38%
Race
White 404,088 18,483,493 2.14%
Black 50,111 3,074,175 1.60%
Other 9,518 684,229 1.37%
Educational Level
Primary 7,482 874,752 0.85%
Secondary 57,420 2,940,637 1.92%
College-Level 23,051 1,550,141 1.47%
Not Available 375,764 16,876,367 2.18%
Marital Status
Never Married 207,904 3,164,284 6.17%
Currently Married 111,295 10,010,622 1.10%
Previously Married 134,779 8,800,899 1.51%
Not Available 9,739 266,092 3.53%
Total 463,717 22,241,897 2.04%

Fig 1. Descriptive demographics of the Substance Use Disorder (SUD) death rates (SUD deaths / total deaths * 1,000) per semester by major demographic groups in the U.S. (2005–2017).

Fig 1

Fig 2. Substance Use Disorders (SUD) death rates per semester by age groups (SUD-related death rates per 1,000 deaths) (A) for the White population (B) for the Black population.

Fig 2

Socioeconomic factors and comorbidities associated with the SUD epidemic

Results from the multilevel mixed effect logistic regression GAM model over the stratified sample are presented in Table 2 for the individual covariates and in Fig 3 for the county-level variables. The statistical characteristics of the stratified sample are described in S1 Table. Five percent of the total number of registered deaths in the U.S. from 2005 to 2017 were included in the sample (1,111,199 deaths, with 22,483 or 2.02% prevalence of SUD-related deaths). We found that age, race, educational level, and marital status were significantly associated with the odds of death by SUD. Individuals aged 25–29 years had the highest odds of SUD-related mortality (odds ratio [OR]: 3.71, 95% confidence interval [CI]: 3.31–4.16) compared to individuals aged 15–19 years, followed by the 30–34 year old age group (OR: 3.65, 95% CI: 3.26–4.09) and 20–24 year old (OR: 2.58, 95% CI 2.30–2.91). Whites had more than double the odds of death by SUD compared to Blacks (OR: 0.45, 95% CI: 0.43–0.47) and other races (OR: 0.45, 95% CI 0.43–0.47). Those with a secondary level education had higher odds of death by SUD (OR: 1.24, 95% CI: 1.10–1.39) compared to those with a primary education. Married individuals had lower odds of SUD-related death than singles (OR: 0.59, 95% CI: 0.57–0.62) and divorced/widowed individuals (OR: 1.19, 95% CI: 0.57–0.62). There was no statistical evidence for a difference in the population odds of SUD-related death for males and females.

Table 2. Odds ratios for the association of demographic factors with death caused by Substance Use Disorders (SUD).

Risk Factor Odds Ratio CI 0.025 CI 0.975 P-value
Age Group
< 15 0.11 0.07 0.17 <0.001
15–19 Ref.
20–24 2.58 2.30 2.91 <0.001
25–29 3.71 3.31 4.16 <0.001
30–34 3.65 3.26 4.09 <0.001
35–39 2.80 2.49 3.14 <0.001
40–44 1.89 1.68 2.11 <0.001
45–49 1.32 1.18 1.48 <0.001
50–54 0.77 0.68 0.86 <0.001
55–59 0.39 0.35 0.44 <0.001
60–64 0.15 0.13 0.17 <0.001
> 64 0.01 0.01 0.02 <0.001
Not Available 0.18 0.08 0.40 <0.001
Sex
Females Ref.
Males 1.00 0.97 1.03 0.933
Race
White Ref.
Black 0.45 0.43 0.47 <0.001
Other 0.45 0.41 0.50 <0.001
Educational Level
Primary Ref.
Secondary 1.24 1.10 1.39 <0.001
College-Level 0.99 0.87 1.13 0.932
Not Available 1.82 1.62 2.04 <0.001
Marital Status
Never Married Ref.
Currently Married 0.59 0.57 0.62 <0.001
Previously Married 1.19 1.14 1.24 <0.001
Not Available 1.39 1.25 1.55 <0.001

All odds ratios estimated using logistic regression generalized additive mixed models.

Fig 3. Generalized additive models estimation for the log odds ratio of death by Substance Use Disorders (SUD) associated with: (A) percentage of children living in poverty, (B) percentage of uninsured population, (C) percentage of the adult population with excessive alcohol consumption, (D) percentage of the adult population that consume tobacco, (E) average of mentally unhealthy days, and (F) average of physically unhealthy days.

Fig 3

The same logistic regression GAM analysis indicated that average number of mentally and physically unhealthy days, percentage of children living in poverty, and percentage of the uninsured population were community-level factors associated with the odds of SUD-related death (S2 Table). The average number of mentally and physically unhealthy days were directly (i.e., positively) associated with an increasing the odds of SUD deaths in individuals living in counties with an average of more than 4.0 of mentally and 4.5 of physically unhealthy days (Fig 3E and 3F, respectively). Children living in poverty and uninsured population percentages showed an inverse relationship, with decreased odds of SUD-related deaths in counties with a percentage population of more than 25% (children living in poverty) and 15% (uninsured population). Lastly, the effects of the average number of mentally and physically unhealthy days on each age group, sex, and race included in our supplement showed dissimilar effects of mentally and physically unhealthy days across demographic groups, especially in the age-group interaction model (S2 Table).

Clustering analysis and spatio-temporal risk estimation

We identified 25 clusters (hotspots) with a significant concentration of SUD-related deaths at the national level from 2005–2017 (S3 Table). The hotspots contained 165,682 (35.73%) of the total reported SUD-related deaths in the U.S., but only included 527 (17.00%) of the 3,111 counties in our clustering and risk estimation analysis. The RR of the hotspots was 1.35 (observed vs. expected SUD deaths) and 2.76% (165,682/5,999,443) of SUD-related deaths relative to all deaths, in comparison to an RR of 0.87 and 1.78% (298,035/16,706,171) in the areas outside the hotspots. Fig 4A shows the location of the SUD-related mortality hotspots, and the spatial distribution of the RR of death by SUD. The estimated RR ranged from 0 to 5.6 and was classified as lowest risk areas (RR < 0.60), low risk (RR: 0.60–1.0), intermediate-risk (RR: 1.00–1.50), high risk (RR: 1.50–2.50), and highest risk (RR> 2.50).

Fig 4.

Fig 4

(A) Spatial distribution of relative risk for death by Substance Use Disorder (SUD) in the contiguous USA (2005–2017) with identified clusters with (enumerated blue circles). (B) Change of the relative risk (first semester 2005 compared to last semester 2017) with identified clusters of substance overdose related deaths (enumerated blue circles).

The highest density of SUD-related death hotspots was located on the border areas of the East North Central, Middle Atlantic, East South Central, and South Atlantic regions, including in the states of Ohio, Pennsylvania, Kentucky, West Virginia, Indiana, and Tennessee (Clusters 1, 3, 5, 8, 23, 25). From 2005 to 2017, 66,227 SUD-related deaths (14.28% of all SUD-related deaths) occurred in these hotspots (RR = 1.44). Additionally, a second area of high relative risk was found in the Pacific and Southwest, including in the states of California, Utah, Colorado, Arizona, Nevada, and New Mexico (Clusters 4, 7, 9, 10, 12, 13, 17, 20, 21, 22) with 38,348 SUD-related deaths (8.26%) and an average RR of 1.49. Finally, areas with the lowest RR were identified in the West North Central regions, with no clusters, and only 21,875 (4.71%) SUD-related deaths in these areas. The average RR in these areas was 0.50 for North Dakota, South Dakota, Nebraska, Iowa, Kansas, Missouri, and Minnesota. Fig 4B describes the temporal trends of SUD-related mortality risk by estimating the percent change between the RR for the first semester of 2005 and the RR for the last semester of 2017. Additional estimates of the RR of SUD-related mortality from the Bayesian Poisson spatial regression analysis are summarized in Table 3 and a detailed description included in the results supplement.

Table 3. Bayesian Poisson regression spatial analysis of the associations between county-level covariates and the relative risk (RR) of death by Substance Use Disorders (SUD).

RR CrI 0.25 CrI 0.975
(Intercept) 0.11 0.08 0.14
Percentage of children living in poverty 0.96 0.96 0.96
Percentage of the population which does not have health insurance (uninsured) 1.01 1.00 1.01
Percentage of adults with excessive alcohol consumption 1.00 0.99 1.01
Percentage of adults consuming tobacco 1.01 1.00 1.01
Average number of mentally unhealthy days 1.39 1.32 1.48
Average number of physically unhealthy days 1.28 1.21 1.35

Values are posterior means of RR, posterior standard deviations (SD) of RR, and 95% credible intervals (CrI) for RR.

Discussion

We found substantial spatial and demographical variation of the SUD epidemic in the U.S. from 2005 to 2017, which was characterized by the emergence of several micro-epidemics of different intensities across demographic groups and locations within the country. We found that the White male population was the group experiencing the highest rates of SUD-related deaths during this timeframe, and according to our results, 33.82% of the total deaths in White males aged 30 to 34 were caused by unintentional drug-related poisoning during the first semester of 2017. The most vulnerable age-groups among White males were 25–29 (31.34% deaths by SUD), and 30–34 (30.71%) in the second semester 2017, which is the most updated data available in our analysis. However, although the White male population was suffering the highest burden of the epidemic during the study period, a striking surge of the epidemic emerged in the Black male population, particularly in ages 30–34 (12.01%), 35–39 (11.88%), 40–49 (11.59%), and 25–29 (11.37%) by the second semester, 2017.

The demographic disparities identified in this study could be the result of a complex system of sub-epidemics fueled by different substances targeting specific demographic groups, and leading different phases of the epidemic [10, 33]. According to our results, the latest stage of the epidemic has been led by prescription opioids, and, since 2013, by synthetic opioids. Early in the epidemic, Black males were one of the most affected populations, impacted by crack-cocaine substances that were fueling this first wave of the SUD epidemic (during early 1990s), but the rapid increasing in the prescribing of opioids in the following phases of the epidemic boosted the SUD-related death mortality in the White population [34]. However, the increased availability of illegal synthetic opioids and heroin has shifted again the epidemic towards the Black population, with an increase in SUD-related Black males’ deaths, particularly in Black males age 45 to 55, who have become one of the most vulnerable populations in the past few years [7].

Additionally, mental and physical distress were found to be key community-level drivers of the SUD epidemic in the country. We found that an additional average day of mental distress might increase the RR of SUD-related mortality by 39% at the county level. Mental health and SUD comorbidity are known as co-occurring disorder or dual diagnosis is a long-known associated illness [3537]. Managing mental illness in SUD patients can be a key factor in the addiction mitigation, due to a higher probability of addiction relapsing in individuals with mental disorders [38]. Moreover, our results suggest mental distress impacted young adults more commonly in locations where the average mentally unhealthy days exceeds 4.02. Furthermore, we found that an additional average day of physical distress might increase the RR of SUD-related mortality by 28%, and this factor was affecting more older adults with a more pronounced effect in the White population. Characteristics of the spatial distribution of physical distress suggest higher levels in the South and Midwest regions of the U.S., potentially associated with a high prevalence of chronic health conditions, smoking, obesity and physical inactivity, especially higher in women and populations with low SES characteristics [39]. These findings have been previously discussed by other researchers. In particular, Case and Deaton’s “Mortality and Morbidity of 21st Century” work included a wider examination of mortality rates of midlife population of the U.S. from 1999–2015 [40]. Among their findings, they reported an increase of death rates due to alcohol, suicide, and overdose related causes and their link with an increase of the physical and mental morbidity on the White population [40]. Our study differs from that of Case and Deaton because we focused only on unintentional drug overdoses in a wider age-groups, which potentially limits the scope of age, income and education role on the SUD-related death risk. However, their study also highlights the role of marital status, and revealed a non-clear association of gender and wealth to the increase of the death rates, matching our results. Moreover, we included an updated data until 2017, that revealed the increasing trend of Black population SUD-related death rates during the last stage of the epidemic from 2015 to 2017. These findings suggest that decreasing physical distress by including preventive measures such as strategies to decrease morbidity of chronic conditions such as cardiovascular diseases, cancer, diabetes, and stroke may help lower SUD when used in conjunction with traditional approaches to prevent or treat SUD [39, 41].

The geographical patterns of the SUD-related mortality observed in our study revealed a series of spatially clustered sub-epidemics with different characteristics within the country. We found that areas in the Midwest surrounding the tri-state border of Ohio, Kentucky, and West Virginia had the highest RR of SUD-related mortality at national level. Counties within this hotspot had a risk of SUD-related death between 2.5 to 5.6 times higher compared to the rest of the country. Other areas with a significant spatial concentration of SUD-related deaths were found among the southern Pacific and mountain divisions in California, Nevada, Utah, Colorado, and New Mexico. The characteristics of the concentration of SUD-related deaths in these areas differ from the above-mentioned synthetic opioid sub-epidemic occurring in the Midwest. These differences included the substances driving the sub-epidemics as well as the temporal trending on SUD-related deaths (Southern Pacific trending decreasing while the Midwest is increasing). The spatiotemporal pattern of the RR of SUD-related deaths suggests a spread of the epidemic from Southwest to Northeast during the period of the study. This progression of the overdose mortality rates is attributed mainly to the interplay between illegal drugs coming from the southern boarders and prescription and synthetic opioids throughout the Midwest and Northeast States [40]. While the epidemic in the Southern Pacific division was fueled by methamphetamines with a substantial amount of heroin overdoses in New Mexico from 2013 onwards, the Northeast region showed a significant increase in the RR of SUD-related deaths and like in the Midwest, this sub-epidemic is led by prescription and synthetic opioids [7]. Both Southwestern and Northeastern areas reported high levels of physical and mental distress, which resulted positive associated to high risk of death by substance overdose in our analyses.

Our study had several limitations worth noting. The main limitation comes from the nature of the data, which relies in the autopsies’ ability to detect and classify substances and circumstances causing the death. Firstly, we used deaths classified as unintentional substance poisoning (ICD-10 codes: X40, X41, X42, X43, X44) to estimate SUD mortality rates, assuming that this classification is a proxy for the mortality rates of the SUD epidemic. This assumption excludes death counts from the overdoses with no information of the self-awareness of harm (IDC-10 codes from Y10 to Y14), and deaths by intentional sef-harm/suicide by substance overdose (IDC-10 codes from X60 to X64), which can be difficult to classify in practice. In addition, drugs causing the overdoses are difficult to categorize, and approximately 20% of the overdose death certificates do not include the involved substance [42]. Even when a drug is listed, a significant number of opioid-related poisonings were classified into the broader categories of other opioids (T40.2) or other and unspecified narcotics (T40.6). Multiple opioids deaths (which were the leading cause of deaths during the last periods) and opioids combined with other drugs were often involved in overdose incidences which did not identify the substance responsible for the overdose. Additionally, autopsies and death certificates can change among states, and our analysis did not take into consideration this variation in the classification for SUD-related mortality. Further efforts are needed to improve the quality of the characterizations of SUD-related deaths, and to standardize substance classification across states, as for example the inclusion of fentanyl into the ICD-10 codes.

Another important limitation is the self-reported nature of the physical and mental distress data, which could produce correlation among covariates, and some bias in our estimations [43]. The selection of our metrics was based on previous studies about the drivers of the addiction diseases, and the availability of the information at national level. Moreover, the BRFSS is designed to provide confident data about the mental and physical distress, and it is widely used by several studies because it includes two important independent health characteristics of the population [9, 44]. Finally, the last limitation is related to our analysis limited to 2017 due to the official source of data for mortality rates is provided always two years behind the current date, which corresponds to the data request process to the CDC which was conducted in 2019.

Despite these limitations, our study is one of the first to conduct a multilevel spatial characterization of the key individual and community-level drivers of the SUD-related mortality in the U.S. Collectively, our results suggest that individual and community-level risk factors are unevenly distributed across different demographic groups, generating a series of sub-epidemics emerging at different times and locations within the country. Moreover, the epidemic has been fueled by the introduction of different substances at different times, impacting the SUD-related mortality rate at different phases of the epidemic. Federal, state, and local governments in the U.S. have implemented multiple intervention measures to decrease SUD-related mortality rates such as restrictions on the prescribing of opioids, efforts to restrict the flow of illicit opioids, and enhancing access to naloxone. Although these efforts, among others, have been relatively successful in decreasing overdose mortality rates in general, the identification of the vulnerable populations and areas that contain the multiple sub-epidemics would enhance the ability to design prevention campaigns, which have proven more effective in managing other diseases than intervention approaches alone [11]. Aligned with the “Know your epidemic, know your response” approach, the detailed spatial and epidemiological description of the vulnerable populations at high risk of SUD-related mortality in the U.S generated in this study can be used to create targeted prevention strategies and to localize intervention campaigns. Microtargeting strategies based on the understanding of the spatial structure and the multifactorial nature of the addiction epidemic would facilitate the design of targeted integrated preventive therapies for early identification of diagnosis in the young adult population [6, 45].

Supporting information

S1 Text. Supplementary methods and results.

(DOCX)

S1 Fig. Discrimination analysis per substance reported as complementary cause of death.

(A) Total population, (B) White males (C), and Black males.

(JPG)

S2 Fig. Detailed demographics of the growth trends.

(Log10 (# Deaths by Substance Use Disorders / # Total Deaths)) of the substance use disorder (SUD) epidemic in the U.S. (2005–2017) by semester.

(JPEG)

S3 Fig. Community-level exposure risk factors for the substance use disorder (SUD)-related mortality.

(A) Percentage of children living under poverty, (B) percentage of the adult population that consume alcohol excessively, (C) percentage of the uninsured population, (D) percentage of the adult population that consumes tobacco, (E) average of mentally unhealthy days, (F) average of physically unhealthy days. All values are averaged from 2010–2017 by county.

(JPEG)

S1 Table. Demographic and socioeconomic characteristics of the stratified sample aggregated by deaths by substance use disorders (SUD) and other causes, 2005 to 2017.

(DOCX)

S2 Table. Complementary results of the generalized additive model association analysis for the county level covariates with the estimated degrees of freedom results for multilevel and factor smooth interaction models.

(DOCX)

S3 Table. Identified clusters of deaths by substance use disorders from the U.S. individual mortality, 2005 to 2017.

(DOCX)

Acknowledgments

The authors thank the U.S. Center for Disease Control and Prevention (CDC) for collecting and releasing the data used in this study.

Data Availability

The data underlying the results presented in the study are available from the U.S. Center for Disease Control and Prevention (CDC) vital statistics (https://www.cdc.gov/nchs/nvss/index.htm).

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Kiang MV, Basu S, Chen J, Alexander MJ. Assessment of Changes in the Geographical Distribution of Opioid-Related Mortality Across the United States by Opioid Type, 1999–2016. JAMA network open. 2019;2(2):e190040–e. 10.1001/jamanetworkopen.2019.0040 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. National Center for Health Statistics, 2020. [Google Scholar]
  • 3.American Society of Addiction Medicine (ASAM). Public Policy Statement: Long Definition of Addiction. 2019. https://www.asam.org/resources/definition-of-addiction.
  • 4.U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health 2016 (NSDUH-2016-DS0001). 2018.
  • 5.Unick GJ, Ciccarone D. US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations. International Journal of Drug Policy. 2017;46:112–9. 10.1016/j.drugpo.2017.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rigg KK, Monnat SM, Chavez MN. Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. International Journal of Drug Policy. 2018;57:119–29. 10.1016/j.drugpo.2018.04.011 [DOI] [PubMed] [Google Scholar]
  • 7.Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361(6408):eaau1184. 10.1126/science.aau1184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mohammad JS, Botticelli M, Hwang R, Koh HK, McHugh RK. The Opioid Crisis: A Contextual Framework and Call for Systems Science Research. working paper. [DOI] [PMC free article] [PubMed]
  • 9.Whitesell M, Bachand A, Peel J, Brown M. Familial, Social, and Individual Factors Contributing to Risk for Adolescent Substance Use. Journal of Addiction. 2013;2013:579310. 10.1155/2013/579310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hernandez A, Branscum AJ, Li J, MacKinnon NJ, Hincapie AL, Cuadros DF. Epidemiological and geospatial profile of the prescription opioid crisis in Ohio, United States. Scientific Reports. 2020;10(1):4341. 10.1038/s41598-020-61281-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wilson D, Halperin DT. Know your epidemic, know your response: a useful approach, if we get it right. The Lancet. 2008;372(9637):423–6. 10.1016/S0140-6736(08)60883-1 [DOI] [PubMed] [Google Scholar]
  • 12.Tran BX, Moir M, Latkin CA, Hall BJ, Nguyen CT, Ha GH, et al. Global research mapping of substance use disorder and treatment 1971–2017: implications for priority setting. Substance abuse treatment, prevention, and policy. 2019;14(1):21-. 10.1186/s13011-019-0204-7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder. The Annals of Family Medicine. 2015;13(1):23. 10.1370/afm.1735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ciancio A, Kämpfen F, Kohler IV, Bennett D, Bruine de Bruin W, Darling J, et al. Know your epidemic, know your response: Early perceptions of COVID-19 and self-reported social distancing in the United States. PLOS ONE. 2020;15(9):e0238341. 10.1371/journal.pone.0238341 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.National Center for Health, Mortality Multiple Cause Data Files. In: Centers for Disease Control and Prevention, US Department of Health and Human Services, editors. 2005–2017.
  • 16.World Health Organization. International classification of diseases for mortality and morbidity statistics (10th Revision). 2019.
  • 17.University of Wisconsin Population Health Institute. County Health Rankings & Roadmaps. 2019.
  • 18.Schulden JD, Thomas YF, Compton WM. Substance abuse in the United States: findings from recent epidemiologic studies. Current psychiatry reports. 2009;11(5):353–9. 10.1007/s11920-009-0053-6 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Patrick ME, Wightman P, Schoeni RF, Schulenberg JE. Socioeconomic status and substance use among young adults: a comparison across constructs and drugs. Journal of studies on alcohol and drugs. 2012;73(5):772–82. 10.15288/jsad.2012.73.772 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Questionnaire. In: Atlanta Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, editors. 2010–2017. [Google Scholar]
  • 21.Murase H, Nagashima H, Yonezaki S, Matsukura R, Kitakado T. Application of a generalized additive model (GAM) to reveal relationships between environmental factors and distributions of pelagic fish and krill: a case study in Sendai Bay, Japan. ICES Journal of Marine Science. 2009;66(6):1417–24. 10.1093/icesjms/fsp105 [DOI] [Google Scholar]
  • 22.Boschetti L, Stehman SV, Roy DP. A stratified random sampling design in space and time for regional to global scale burned area product validation. Remote sensing of environment. 2016;186:465–78. Epub 2016/09/20. 10.1016/j.rse.2016.09.016 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2011;73(1):3–36. 10.1111/j.1467-9868.2010.00749.x [DOI] [Google Scholar]
  • 24.Hastie T, Tibshirani R. Generalized Additive Models1990. [DOI] [PubMed]
  • 25.Van Rossum G, Drake Jr FL. Python tutorial: Centrum voor Wiskunde en Informatica Amsterdam, The Netherlands; 1995.
  • 26.Zaharia Ma, X RSa, W Pa, D Ta, A Ma, D Aa, M Xa, R Ja, V Sa, F MJ. Apache Spark: A Unified Engine for Big Data Processing. Commun ACM. 2016;59(11):56–65. 10.1145/2934664 [DOI] [Google Scholar]
  • 27.R Development Core Team. R: A Language and Environment for Statistical Computing. 2008. [Google Scholar]
  • 28.Wood SN. Generalized Additive Models: An Introduction with R. 2 ed: Chapman and Hall/CRC; 2017. [Google Scholar]
  • 29.Kulldorff M, National Cancer Institute. SaTScan v9.0: software for the spatial and space-time statistics. 2010.
  • 30.Besag J, York J, Mollié A. Bayesian image restoration, with two applications in spatial statistics. Annals of the Institute of Statistical Mathematics. 1991;43(1):1–20. 10.1007/BF00116466 [DOI] [Google Scholar]
  • 31.Blangiardoa M, Camelettib M, Baiocd G, Rue H. Spatial and spatio-temporal models with R-INLA. Spatial and Spatio-temporal Epidemiology. 2013;4:33–49. 10.1016/j.sste.2012.12.001 [DOI] [PubMed] [Google Scholar]
  • 32.Hadley W. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag; New York; 2016. [Google Scholar]
  • 33.Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis2019. [DOI] [PMC free article] [PubMed]
  • 34.Dunlap E, Golub A, Johnson BD. The Severely-Distressed African American Family in the Crack Era: Empowerment is not Enough. Journal of sociology and social welfare. 2006;33(1):115–39. . [PMC free article] [PubMed] [Google Scholar]
  • 35.Hawkins EH. A Tale of Two Systems: Co-Occurring Mental Health and Substance Abuse Disorders Treatment for Adolescents. Annual Review of Psychology. 2008;60(1):197–227. 10.1146/annurev.psych.60.110707.163456 [DOI] [PubMed] [Google Scholar]
  • 36.Harris KM, Edlund MJ. Use of Mental Health Care and Substance Abuse Treatment Among Adults With Co-occurring Disorders. Psychiatric Services. 2005;56(8):954–9. 10.1176/appi.ps.56.8.954 [DOI] [PubMed] [Google Scholar]
  • 37.Watkins KE, Hunter SB, Wenzel SL, Tu W, Paddock SM, Griffin A, et al. Prevalence and Characteristics of Clients with Co‐Occurring Disorders in Outpatient Substance Abuse Treatment. The American Journal of Drug and Alcohol Abuse. 2004;30(4):749–64. 10.1081/ada-200037538 [DOI] [PubMed] [Google Scholar]
  • 38.Norman SB, Tate SR, Anderson KG, Brown SA. Do trauma history and PTSD symptoms influence addiction relapse context? Drug and Alcohol Dependence. 2007;90(1):89–96. 10.1016/j.drugalcdep.2007.03.002 [DOI] [PubMed] [Google Scholar]
  • 39.Chen H-Y, Baumgardner D, Rice J. Health-related quality of life among adults with multiple chronic conditions in the United States, Behavioral Risk Factor Surveillance System. Prev Chronic Dis . [PMC free article] [PubMed] [Google Scholar]
  • 40.Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proceedings of the National Academy of Sciences. 2015;112(49):15078. 10.1073/pnas.1518393112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. PAIN. 2007;129(3). 10.1016/j.pain.2007.02.014 [DOI] [PubMed] [Google Scholar]
  • 42.Rudd R, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths—United States, 2010–2015. 2016. [DOI] [PubMed]
  • 43.Dwyer-Lindgren L, Mackenbach JP, van Lenthe FJ, Mokdad AH. Self-reported general health, physical distress, mental distress, and activity limitation by US county, 1995–2012. Population Health Metrics. 2017;15(1):16. 10.1186/s12963-017-0133-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ahluwalia IB, Mack KA, Mokdad A. Mental and Physical Distress and High-Risk Behaviors Among Reproductive-Age Women. Obstetrics & Gynecology. 2004;104(3). 10.1097/01.AOG.0000137920.58741.26 [DOI] [PubMed] [Google Scholar]
  • 45.Holmes CB, Rabkin M, Ford N, Preko P, Rosen S, Ellman T, et al. Tailored HIV programmes and universal health coverage. Bulletin of the World Health Organization. 2020;98(2):87–94. 10.2471/BLT.18.223495 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Arsham Alamian

1 Feb 2021

PONE-D-20-31970

“Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

PLOS ONE

Dear Dr. Cuadros,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. 

Please submit your revised manuscript by Mar 18 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Arsham Alamian, PhD, MSc, FACE

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2) You indicated that ethical approval was not necessary for your study. We understand that the framework for ethical oversight requirements for studies of this type may differ depending on the setting and we would appreciate some further clarification regarding your research. Could you please provide further details on why your study is exempt from the need for approval and confirmation from your institutional review board or research ethics committee (e.g., in the form of a letter or email correspondence) that ethics review was not necessary for this study? Please include a copy of the correspondence as an "Other" file.

3) Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: “Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

This manuscript describes the substance use disorder epidemic that is currently occurring in the United States. Although SUD is occurring at very high rates, not enough information is known about the demographics or socioeconomic factors related to individuals using substances. This study used data obtained from the CDC from 2005-2017 to examine characteristics of SUD. Findings were that White males consistently had highest SUD mortality rate from 2005-2017. There was a surge of increase in mortality in Black males from 2014-2017. SUD clustering showed there were more clusters in the west and Midwest. The researchers also found that having mental health distress or conditions significantly increased the relative risk of acquiring SUD. Overall, this is a very interesting manuscript that contributes to the scientific literature. However, the writing could be more clear at times. Suggestions for improvement are provided below:

Abstract:

1. For this sentence in the conclusion “we found that this sad epidemic in the U.S. is characterized by…” I got confused with “sad” standing for substance abuse disorder – perhaps change to SUD or rephrase

2. For the first sentence in the results section, consider spelling out “U.S.” to United States so it is more clear that the next sentence begins with “white”, otherwise this appears to be a run on sentence.

Introduction:

1. Regarding the definition of SUD, the manuscript states that the person that engages in the behavior has knowledge of the harmful consequences of engaging in excessive substance use. However, how is this measured and how do we know the individual is aware of the harm? In the research methods section the data collected is about substance use and behavior, not knowledge of the behavior.

2. End of page 3, states that “know your epidemic, know your response” framework shifted from coercive strategies to targeted prevention strategies. What does this mean? How were they coercive before, how did the shift occur to targeted prevention, and clarify what this means?

Methods:

1. Page 5, second to last paragraph, last sentence should be “publicly” (not publicity)

2. The statistical methods seem to be adequately explained and appropriately applied to the data set.

Results:

1. Page 7, paragraph 1 – for the sentence that says mortality in Black males has risen sharply since 2014, 40.00 SUD-related deaths per 1,000 total deaths is listed, however I would like to see a comparison number for white males.

2. Page 7 – table 1, figure 1 and figure 2 use the terminology substance abuse disorder (SAD) while the rest of the manuscript has been using substance use disorder (SUD) – clarification is needed here

3. Page 8, paragraph 1 – states that there is no statistical difference in population odds of SUD-related death for males and females, this needs clarification as males suffer from disproportionately high SUD and have shown highest mortality 2005-2017 stated multiple places elsewhere.

Discussion:

1. Middle paragraph on page 11 – the description of the epidemic in the southern Pacific/mountain region is a little unclear to me. 2-3 more sentences of elaboration would be helpful to contrast with the epidemic occurring in the Midwest and other regions.

2. Appropriate limitations are mentioned.

Figures:

1. Figure 2 – description of the figure and short analysis contrasting A and B would be helpful/useful

2. Figure 4 – B – clarify ‘intentional’ substance use disorders

Recommendation: Accept subject to revision

Reviewer #2: Re: PONE-D-20-31970

Diego Cuadros

“Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

1. Topic of considerable interest given Case and Deaton’s PNAS paper and book on “Deaths of Despair” and the noted increased mortality due to suicide, overdose, accidents in select groups in the last 5-8 years.

2. The authors identify areas in the U.S. with increase deaths by SUD using CDC data 2005-2017.

3. Methodology excellent

4. Results

Increase of death due to SUD

Males

White with a sharp increase in Blacks since 2014

Increase 25-29, higher education (Did they look at college/no college, single, divorced, poverty, physical illness?)

Certain States, Mid-West followed by Southern Pacific, Mountain States, and North East States showed increase.

The opportunity to check out the Case and Deaton findings on education is partially lost by the absence of 2.18% of the data on education. The figures are presented for primary/secondary/college level. Can the authors look further at college graduate vs. others?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 May 26;16(5):e0251502. doi: 10.1371/journal.pone.0251502.r002

Author response to Decision Letter 0


23 Feb 2021

We appreciate the opportunity to resubmit our work to the journal. We would like to thank the editor and the reviewers for assessing our work and for their valuable feedback and suggestions that have improved our manuscript. Please find below a point-by-point reply that addresses each of the journal and the reviewers’ comments. We have also incorporated these suggestions in the revised manuscript as noted below. We would be pleased to address any further points that the editor or reviewers may find unsatisfactory.

JOURNAL COMMENTS:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Style requirements were followed in the revised version of the manuscript according to the guidelines provided by the journal, including the file naming patterns.

2. You indicated that ethical approval was not necessary for your study. We understand that the framework for ethical oversight requirements for studies of this type may differ depending on the setting and we would appreciate some further clarification regarding your research. Could you please provide further details on why your study is exempt from the need for approval and confirmation from your institutional review board or research ethics committee (e.g., in the form of a letter or email correspondence) that ethics review was not necessary for this study? Please include a copy of the correspondence as an "Other" file.

As we stated in our manuscript, we used for our analyzes the publicly available vital statistics micro-data from the Centers for Disease Control (CDC) compiled by the National Center for Health Statistics (NCHS) (https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm). These data are neither identifiable nor private and thus do not meet the federal definition of “human subject” as defined in 45 CFR 46.102. Therefore, these research projects do not need to be reviewed and approved by an Institutional Review Board, (IRB). For your reference, a similar study using the same data sources as our study and published last year in the journal also stated that because their study involved analysis of existing, deidentified data, it was exempt from human subjects review (“Glei, Dana A., and Samuel H. Preston. "Estimating the impact of drug use on US mortality, 1999-2016." PloS one 15.1 (2020): e0226732.)

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly.

The supporting information captions were included at the end of the manuscript according to the style of the reference provided by the editor. (Page 20, Line 1, Supporting Information Section)

REVIEWER COMMENTS:

REVIEWER 1

Abstract:

1. For this sentence in the conclusion “we found that this sad epidemic in the U.S. is characterized by…” I got confused with “sad” standing for substance abuse disorder – perhaps change to SUD or rephrase

We appreciate the feedback of the reviewer. The term Substance Use Disorder (SUD) replaced all other related abbreviations along the manuscript for consistency, accordingly to the reviewer suggestion. (Page 2, line 3, Abstract section), (Page 2, line 16, Abstract section), (Page 8, line 16, Table 1 caption), (Page 8, line 18, Fig 1 caption), (Page 8, line 20, Fig 2 caption), (Page 10, line 4, Table 2 caption), (Page 10, line 7, Fig 3 caption), (Page 12, line 5, Fig 4 caption), (Page 13, line 2, Table 3 caption), (Page 12, line 5, Discussion section).

2. For the first sentence in the results section, consider spelling out “U.S.” to United States so it is clearer that the next sentence begins with “white”, otherwise this appears to be a run on sentence.

The suggestion was included in the reviewed version of the manuscript. (Page 2, line 11, Abstract section).

Introduction:

1. Regarding the definition of SUD, the manuscript states that the person that engages in the behavior has knowledge of the harmful consequences of engaging in excessive substance use. However, how is this measured and how do we know the individual is aware of the harm? In the research methods section the data collected is about substance use and behavior, not knowledge of the behavior.

We appreciate the feedback from the reviewer, and we agree with the reviewer about the need of further clarification of the definition of Substance Use Disorders (SUD) mortality. Our research methods focus on the analysis of unintentional (accidental) deaths by substance overdose as defined by the ICD10 standard for causes of death codes X40, X41, X42, X43, X44. The other causes of deaths including codes X60, X61, X62, X63, X64 (Deaths by Intentional Self- harm/Suicide caused by substance overdose), and deaths with no information about the self-intention (codes Y10, Y11, Y12, Y13, Y14) were used as control events (outcome ‘0’) in our binary outcome. This choice made the assumption that death by accidental substance overdose is a proxy for the mortality of substance abuse disorders that does not include the intention of self-harm. This choice was based on the literature review and implies some limitations worth noting. As a result of the reviewer suggestion, we included in the revised version of the manuscript a mention to this limitation as the data source does not specify previous medical history of deceased individuals. (Page 14, line 14, Discussion section, limitations).

2. End of page 3, states that “know your epidemic, know your response” framework shifted from coercive strategies to targeted prevention strategies. What does this mean? How were they coercive before, how did the shift occur to targeted prevention, and clarify what this means?

“Know your epidemic, know your response” is a framework that prioritize preventive approaches (e.g., education campaigns, targeting cause of epidemics) more than reactive measures (e.g., vaccination, medical treatment) for mitigating epidemics. In principle, this framework has been proposed to target HIV, however several studies reported that components of this approach are also applicable to other epidemics. Additionally, this framework states that the individual’s knowledge about risk is critical for the ability to respond epidemics with risk reduction strategies, and the individual social behaviors are determinants on the prevalence of the epidemics. As a suggestion of the reviewer’s feedback, we include an updated bibliography highlighting the aforementioned elements, and rephrasing the concept of coercive strategies for clarifying in the reviewed version of the manuscript. (Page 4, line 4, Introduction section).

Methods:

1. Page 5, second to last paragraph, last sentence should be “publicly” (not publicity)

We appreciate the careful examination of the reviewer. We included the suggestion in the reviewed version of the manuscript. (Page 5, line 20, Methods, Data source Description section).

Results:

1. Page 7, paragraph 1 – for the sentence that says mortality in Black males has risen sharply since 2014, 40.00 SUD-related deaths per 1,000 total deaths is listed, however I would like to see a comparison number for white males.

As a result of the reviewer’s suggestion. We included in the revised version of the manuscript the comparison of the temporal trend of SUD-related deaths of black and white males. (Page 7, line 11, Results section).

2. Page 7 – table 1, figure 1 and figure 2 use the terminology substance abuse disorder (SAD) while the rest of the manuscript has been using substance use disorder (SUD) – clarification is needed here

We appreciate the feedback of the reviewer. The term Substance Use Disorder (SUD) was included along all the manuscript accordingly to the reviewer suggestion. (Page 2, line 3, Abstract section), (Page 2, line 16, Abstract section), (Page 8, line 16, Table 1 caption), (Page 8, line 18, Fig 1 caption), (Page 8, line 20, Fig 2 caption), (Page 10, line 4, Table 2 caption), (Page 10, line 7, Fig 3 caption), (Page 12, line 5, Fig 4 caption), (Page 13, line 2, Table 3 caption), (Page 12, line 5, Discussion section).

3. Page 8, paragraph 1 – states that there is no statistical difference in population odds of SUD-related death for males and females, this needs clarification as males suffer from disproportionately high SUD and have shown highest mortality 2005-2017 stated multiple places elsewhere.

Taking into account the suggestion of the reviewer, we added in the discussion section further mention about this result, and we included new bibliography that analyzed this topic with similar results as ours. Even though we agree with the reviewer that men suffer a disproportionately high SUD-related deaths, our association analysis resulted in a non-significant effect of gender on the risk of death by SUD likely caused by the relationship between gender, morbidity and other socioeconomic factors included in our adjusted model. (Page 13, line 14, Discussion section).

Discussion:

1. Middle paragraph on page 11 – the description of the epidemic in the southern Pacific/mountain region is a little unclear to me. 2-3 more sentences of elaboration would be helpful to contrast with the epidemic occurring in the Midwest and other regions.

As a result of the suggestion of the reviewer, we add more details and updated bibliography regarding the differences of the epidemic occurring in the Midwest and North East compared to the southern Pacific/mountain regions. (Page 14, line 2, Discussion section).

Figures:

1. Figure 2 – description of the figure and short analysis contrasting A and B would be helpful/useful

We added further comparison among the rates between black and white male population in Figure 2. We also rounded the morality rates to 2 decimals to compute the percentage of increasing rates for black and white males from 2014 to 2015. (Page 7, line 6, Abstract section).

2. Figure 4 – B – clarify ‘intentional’ substance use disorders

We appreciate the feedback of the reviewer and we agree with the need of clarification about the use of ‘intentional’ and ‘unintentional’ in the context of death by substance overdose. Our research methods include unintentional accidental deaths by substance overdose as defined by the ICD10 codes for causes of death X40, X41, X42, X43, X44. The other causes of deaths including codes X60, X61, X62, X63, X64 (Deaths by Intentional Self- harm/Suicide caused by substance overdose) and Y10, Y11, Y12, Y13, Y14 (Undetermined intent substance overdose death) were used as control cases in our binary outcome. This clarification is included in the reviewed version of the manuscript. (Page 14, line 14, Discussion section).

REVIEWER 2

1. Topic of considerable interest given Case and Deaton’s PNAS paper and book on “Deaths of Despair” and the noted increased mortality due to suicide, overdose, accidents in select groups in the last 5-8 years.

We appreciate the interesting insights of the reviewer. We also agree that the reference the author is citing is an important piece of the literature related to our study, given the fact they used the same data source for the death counts (CDC Wonder micro-files), and validated some of our findings. As a result, we added this reference to our bibliographic review in the revised version of our manuscript and included more details to the discussion based on the findings of Case and Deaton’s work. (Page 19, line 14, Reference section).

4. Results

Increase 25-29, higher education (Did they look at college/no college, single, divorced, poverty, physical illness? The opportunity to check out the Case and Deaton findings on education is partially lost by the absence of 2.18% of the data on education. The figures are presented for primary/secondary/college level. Can the authors look further at college graduate vs. others?

Our study reported the results from a statistical association analysis between the individual risk of death caused by unintentional substance poisoning and several demographic and socio-economic covariates, including (age group, gender, education, socio economic status and marital status), as well as self-reported days of physical and mental distress from the Behavioral Risk Factor Surveillance System averaged for the time period of 2010 – 2017 and aggregated at the county level.

From the results of our association analysis, we agree with the reviewer that Case and Deaton’s research is an important piece of the literature to be discussed within the context of our study. However, Case and Deaton study shows several differences and similarities with our study that are worth noting because they limit our ability to compare both findings of both studies, especially in the relationship of educational level and SUD-related death risk. As a result of the reviewer’s suggestion, we summarized the similarities and differences of our study with the Case and Deaton’s work and included them in the revised version of our manuscript. (Page 13, Lines 10, Discussion section)

Among similarities and differences, Case and Deaton’s research offers a wider range of death causes than the focus of our study. They also concentrated a significant portion of their study on midlife adults, and highlighted suicides, alcohol-related and overdose as one of the critical drivers of the mortality rates increase for whites non-hispanic (WNH) in the United States. In addition, they found that educational level was critical for several aspects of the death rate increment from 1999 - 2015. In our study, we excluded intentional self-harm, and other substances apart from (Heroin, Methadone, Other opioids, synthetic narcotics, cocaine, unspecified narcotics) and included a wider range of age groups (from 5 to 84 years). As age is related to educational level, this could explain that college education did not show statistical significance, but high school resulted in an associated factor for the increased risk of SUD-related death.

Another difference is the time range of both studies. While Case and Deaton’s focused from 1999 to 2015, our study was conducted from 2005 to 2017. This is especially important because Case and Deaton study reported an increase of WNH death rates from 1999 to 2015, and a parallel decrease of death rates for Blacks and Hispanic population on the same period. Our study shows that Black SUD-related death rates rised sharply from 2013 and reach the WNH SUD-related death rates in 2017, period which was out of the scope of the Case and Deaton’s study.

Finally, Case and Deaton were similar to our methods in the use of the same data sources for the computation of mortality rates, and a resulting increase of morbidity of physical and mental health linked to the increase of death rates. This offers an interesting insight to our study because they exposed the lack of job opportunities and education as a potential cause of the increasing death rates. In addition, they validated our spatiotemporal pattern which suggest a diffusion of the epidemic from the Southwest to the North Eastern and Mideastern states and an unclear association between gender and wealth with an increasing of alcohol, suicide and overdose related death rates that is a super set of the SUD-related mortality rates of our study.

Attachment

Submitted filename: Response_Reviewers_Feb23.pdf

Decision Letter 1

Arsham Alamian

28 Apr 2021

“Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

PONE-D-20-31970R1

Dear Dr. Cuadros,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Arsham Alamian, PhD, MSc, FACE

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This version of the manuscript is much better. I believe both my comments and the other reviewer's comments appear to be addressed. Good detail that elaborates on the differing epidemics in South vs Midwest, helpful clarification was provided regarding statistical analysis as well. Overall good job. I feel that this manuscript needs no further revision at this point.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Kathryn Gerber

Acceptance letter

Arsham Alamian

3 May 2021

PONE-D-20-31970R1

“Know your epidemic, know your response”: Epidemiological assessment of the substance use disorder crisis in the United States

Dear Dr. Cuadros:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Arsham Alamian

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. Supplementary methods and results.

    (DOCX)

    S1 Fig. Discrimination analysis per substance reported as complementary cause of death.

    (A) Total population, (B) White males (C), and Black males.

    (JPG)

    S2 Fig. Detailed demographics of the growth trends.

    (Log10 (# Deaths by Substance Use Disorders / # Total Deaths)) of the substance use disorder (SUD) epidemic in the U.S. (2005–2017) by semester.

    (JPEG)

    S3 Fig. Community-level exposure risk factors for the substance use disorder (SUD)-related mortality.

    (A) Percentage of children living under poverty, (B) percentage of the adult population that consume alcohol excessively, (C) percentage of the uninsured population, (D) percentage of the adult population that consumes tobacco, (E) average of mentally unhealthy days, (F) average of physically unhealthy days. All values are averaged from 2010–2017 by county.

    (JPEG)

    S1 Table. Demographic and socioeconomic characteristics of the stratified sample aggregated by deaths by substance use disorders (SUD) and other causes, 2005 to 2017.

    (DOCX)

    S2 Table. Complementary results of the generalized additive model association analysis for the county level covariates with the estimated degrees of freedom results for multilevel and factor smooth interaction models.

    (DOCX)

    S3 Table. Identified clusters of deaths by substance use disorders from the U.S. individual mortality, 2005 to 2017.

    (DOCX)

    Attachment

    Submitted filename: Response_Reviewers_Feb23.pdf

    Data Availability Statement

    The data underlying the results presented in the study are available from the U.S. Center for Disease Control and Prevention (CDC) vital statistics (https://www.cdc.gov/nchs/nvss/index.htm).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES